Asthma, COPD, Lung Cancer News | Treatment & Research Articles
The 2025 GOLD COPD report includes a new emphasis on CV disease and PH in COPD and major updates on spirometry, new COPD drugs, climate change, and more.
GOLD COPD Report 2025: Key Spirometry and Drug Updates
Nov 22, 2024 · The 2025 GOLD COPD report includes a new emphasis on CV disease and PH in COPD and major updates on spirometry, new COPD drugs, climate change, and more. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its 2025 updated version of the GOLD Chronic Obstructive Pulmonary ...
2024 GOLD Report Reflects New Research on COPD Management
Dec 8, 2023 · The 2024 GOLD Report, “Global Strategy for Prevention Diagnosis and Management of COPD,” not only includes guideline updates that reflect the latest research on chronic obstructive pulmonary disease (COPD); it also reflects some shifts in thinking about what’s important in COPD treatment, according to Claus Vogelmeier, MD, a lead report author and science committee chair for the Global ...
GINA 2024 Asthma Update: Revised Recommendations on …
Jun 28, 2024 · The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more.
Acute Exacerbations of COPD More Likely With CT-Detected …
Dec 9, 2024 · The COPDGene (n=3250) and ECLIPSE (n=1716) cohorts comprised 54.9% and 63.7% men, respectively. Patients were a mean (SD) age of 63.7 (8.4) and 63.3 (7.1) years, 38.3% and 37.2% were current smokers, and 38.7% and 45.6% experienced an acute exacerbation in the year before study enrollment, respectively.
2024 GOLD Guidelines Stress the Importance of Vaccines for …
Jan 5, 2024 · Credit: Getty Images Patients with stable COPD should receive vaccinations for influenza, pneumococcal pneumonia, herpes zoster, RSV, and COVID-19, according to 2024 GOLD COPD guidelines.
News And Features - Pulmonology Advisor
GOLD COPD 2025 Report: Key Spirometry and Drug Updates, New Emphasis on CVD, PH
Dupixent Approved as Add-On Maintenance Therapy in COPD
Oct 1, 2024 · The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.. The approval was supported by data from the randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS (ClinicalTrials.gov Identifier ...
Updated 2023 GOLD Report Revises COPD Definitions and …
Jan 20, 2023 · The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
Treating Severe Uncontrolled Asthma: Can Single-Inhaler, Fixed …
In everyday clinical practice, stratifying patients with asthma using specific clinical features and biomarkers, as summarized in Table 1, allocates most patients to either allergic-predominant or eosinophilic-predominant T2-high asthma to allow selection of appropriate treatment. 4 For example, the anti-IgE agent omalizumab is the treatment of choice for a …